You are here

Share:

Co-Development Agreements

The National Cancer Institute's Technology Transfer Center (TTC) recognizes the importance of co-development in order to translate early-stage discoveries to outside entities to benefit public health. In support of this goal, the TTC establishes formal collaborative agreements with industry, academia, and non-profits to facilitate co-development through the exchange and development of research materials, knowledge, and technologies.
 
The TTC uses three different co-development agreements to help industry and academia interact and partner with National Institutes of Health laboratories and scientists to support technology development activities:
 
Agreements Purpose Essential Elements
Collaboration Agreement (CA) Permits a two-way exchange of materials and information, and assumes exchange of results and/or conclusions will occur between NIH and companies, universities, state/local governments, Federal labs, and non-profits.
- Combines terms of a CDA and MTA
- Simplified research plan
- Exchange of new material created during the collaboration is  addressed
- No funding from the outside party allowed
- No license option
- Rights to foreground IP are not addressed
- Human and non-human materials covered
 
Cooperative Research and Development Agreement (CRADA) Permits co-development of NIH or outside invention involving companies, universities, state/local governments, Federal labs, and non-profits.
For NIH:
- May receive funds or in-kind contributions for collaborative research project
- May provide confidentiality for research results up to five years after development 
 
For Collaborator:
- Option to exclusively license any inventions that are developed by a Federal laboratory employee(s) as part of the collaborative research    
- Access to unique reagents and resources
- Access to scientific and regulatory expertise
- Access to Federal lab
 
Clinical Trial Agreement (CTA) Transfers material into NIH for research in Human Subjects from companies, state/local governments, non-profits, universities 
- Covers investigational data, drug, diagnostic, or device
- No funding from the outside party required
- No option to license foreground IP
- Clinical and non-clinical
- Addresses regulatory issues and monitoring
- Addresses Personally Identifiable Information (PII)
 

 

 

Updated
Friday, February 19, 2016